Radio and PodcastLive Radio & PodcastsScience & Medicine
107 - CymaBay Sets to Massively Improve Outcomes in PBC Patients Interview with CEO Sujal Shah
CymaBay Therapeutics is developing Seladelpar for the treatment of Primary Biliary Cholangitis (PBC). PBC currently affects around 130K patients in the USA and current available treatments do not address patient needs su...
About This Episode
107 - CymaBay Sets to Massively Improve Outcomes in PBC Patients Interview with CEO Sujal Shah is an episode from Breaking Biotech by Matthew Lepoire. CymaBay Therapeutics is developing Seladelpar for the treatment of Primary Biliary Cholan...
Podcast
This episode belongs to Breaking Biotech.
Listen Online
Use the player on this page to stream the episode online.
Episode Details
Published Jan 29, 2022, 00:35:09 long, audio available.
Related Episodes
Continue listening to more episodes from Breaking Biotech.
112 - Biotech Updates - $BTAI $TGTX $CRIS $CKPT $KPTI $SRRA
Apr 21, 2022 - 00:43:59
111 - Achieve Life Sciences Phase 3 Readout Imminent! Interview with CEO John Bencich
Apr 1, 2022 - 00:28:19
109 - Karyopharm Guides INCREASED Sales Growth in 2022 and Reports Positive SIENDO Results
Feb 22, 2022 - 00:33:42
108 - NASH Companies to Watch in 2022! Madrigal Pharma Announces Positive Data in NAFLD
Feb 7, 2022 - 00:37:28
106 - Bright Spot Among CRISPR in Caribou Biosci. 2022 Biotech Trends to Watch!
Jan 9, 2022 - 00:42:53